Your browser doesn't support javascript.
loading
Exploiting mesoporous silica, silver and gold nanoparticles for neurodegenerative diseases treatment.
Ribeiro, Taís C; Sábio, Rafael M; Carvalho, Gabriela C; Fonseca-Santos, Bruno; Chorilli, Marlus.
Afiliação
  • Ribeiro TC; São Paulo State University - UNESP, School of Pharmaceutical Sciences, Department of Drugs and Medicines, Araraquara, São Paulo 14801-903, Brazil.
  • Sábio RM; São Paulo State University - UNESP, School of Pharmaceutical Sciences, Department of Drugs and Medicines, Araraquara, São Paulo 14801-903, Brazil. Electronic address: rafael.m.sabio@unesp.br.
  • Carvalho GC; São Paulo State University - UNESP, School of Pharmaceutical Sciences, Department of Drugs and Medicines, Araraquara, São Paulo 14801-903, Brazil.
  • Fonseca-Santos B; Department of Biotechnology, Health Sciences Institute, Federal University of Bahia (UFBA), Salvador, Bahia 40170-115, Brazil.
  • Chorilli M; São Paulo State University - UNESP, School of Pharmaceutical Sciences, Department of Drugs and Medicines, Araraquara, São Paulo 14801-903, Brazil. Electronic address: marlus.chorilli@unesp.br.
Int J Pharm ; 624: 121978, 2022 Aug 25.
Article em En | MEDLINE | ID: mdl-35792231
Neurodegenerative diseases (NDs) are considered public health problem characterized by neural loss causing cognitive and behavioral impairments. It is currently possible to use drugs capable of controlling the symptoms caused by these diseases. However, treatment is not able to prevent neural loss. In addition, poor solubility, low bioavailability due to the inability for crossing the blood-brain barrier (BBB) are described as the main limitations of the treatment. Nanotechnology involves the development of nanoscale drug delivery systems and they have been employed to optimize therapeutics face to several diseases treatment. In light of this, this review describes the highlights on the fabrication of nanotechnology-based drug delivery systems emphasizing mesoporous silica, gold and silver nanoparticles (MSNs, AuNPs and AgNPs, respectively) and their biological behavior for the treatment of Alzheimer's and Parkinson diseases (ADs and PDs, respectively).
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Neurodegenerativas / Nanopartículas / Nanopartículas Metálicas Limite: Humans Idioma: En Revista: Int J Pharm Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Brasil País de publicação: Holanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Neurodegenerativas / Nanopartículas / Nanopartículas Metálicas Limite: Humans Idioma: En Revista: Int J Pharm Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Brasil País de publicação: Holanda